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Abstract 
 
Primary malignant melanoma of the vagina is rare but aggressive. Various treatment options include surgery and 
adjuvant therapy has been advocated but the outcome remained unpredictable. Standard treatment protocol is yet to 
be established. We report a case of 54-year-old, Para 4+1, with malignant melanoma of the vagina. She underwent 
wide local excision but the surgical margin was not clear of malignant cells, hence adjuvant radiotherapy was given. 
Combination chemotherapy was initiated subsequently as her disease disseminated. She succumbed later due to 
septicaemic shock. The treatment options for vaginal melanoma were reviewed. 
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Introduction 
 
Primary malignant melanoma of the vagina is rare. 
Biologically, this tumor is known to be aggressive. The 
reported incidence was <10% of all melanoma and 
<5% for all cancers of the female urogenital tract (1). It 
affects mostly post-menopausal women and the median 
age upon diagnosis is at sixth decades of life (2,3,4). 
The overall 5 years survival rate was poor between 20-
27% (3,5). Various treatment options include surgery 
and adjuvant therapy has been advocated but the 
outcome remained unpredictable. Standard treatment 
protocol is yet to be established (6,7). We here report a 
case of recurrent primary malignant melanoma of the 
vagina. The treatment options were reviewed. 
 
Case Report 
 
A 54-year-old, Para 4+1, post menopausal for four 
years was not on hormone replacement therapy. She 
first presented with vaginal growth and abnormal 
vaginal discharge for 6 months duration associated 
with pruritus vulvae. She had no remarkable medical 
or surgical history except dyslipidaemia. There was no 
significant family history of gynaecological 
malignancy.  
 
Upon examination, there was a raised, pigmented 
growth measuring 30 x 20 mm located at the upper 
third of anterior vaginal wall. There was no ulceration 
or bleeding. No palpable inguinal or pelvic lymph 
node was noted. Other examination was unremarkable. 
 
She underwent wide local excision of the vaginal 
lesion. The histopathological examination (HPE) 
showed malignant cell infiltration arranged in nests, 
islands and sheets. The malignant cells were large 
pleomorphic with hyperchromatic nuclei and 
containing large amount of dark pigment (melanin) in 
the cytoplasm. These cells stained positive with S100, 
HMB45 and Melan A but CK was negative (Fig. 1). 
The final diagnosis was malignant vaginal melanoma. 
Unfortunately, the surgical margin was not clear of 
malignant cells.  
Case Report 
Primary malignant vaginal melanoma                                                                                                                                Ng BK et al. 
 
Journal of Surgical Academia 2014; 4(1):63-66   64 
 
She defaulted follow-up and presented six months later 
with vaginal mass and vaginal bleeding. She was then 
given external beam radiotherapy for three fractions in 
a week in view of persistent per vaginal bleeding as 
she refused any additional surgical intervention. 
 
One month following radiotherapy, her MRI pelvis 
(Fig. 2) showed local recurrence with presence of 
well-circumscribed vaginal mass. Unfortunately, the 
disease also progressed systemically to the lung. She 
received six cycles of combination chemotherapy-
CVD regime (Cisplatin, Vinblastine and Dacarbazine). 
 
Despite multimodality therapy, her disease progressed 
to involve the lung, liver, subcutaneous, peritoneal and 
lymph nodes. She succumbed two months later due to 
infected chemoport with septicaemic shock.  
 
Discussion 
 
Primary malignant melanoma of vagina is a rare entity. 
The most common presenting symptom is vaginal 
bleeding (3). Other presentations include palpable 
vaginal mass, pain, vaginal discharge and itching (8). 
The lesions commonly found at lower third of vagina 
in up to 65% of patients (3). In this review, Das et al. 
reported several unusual sites of primary malignant 
melanoma, which include cervix, ovary, urethra, 
rectum, nasal cavity, tongue, breast, tonsillar fossa and 
cerebral cortex (9). In the present case, the patient 
presented with a mass situated at the upper third of 
vagina associated with itchiness and abnormal vaginal 
bleeding. 
Various treatment approaches have been attempted. 
However, to date, there is still lacking of proper 
guideline or standard treatment protocol. Surgical 
options ranged from simple WLE to more radical 
approach such as total vaginectomy and pelvic 
exenteration.   
 
The role of lymph node dissection remains debatable. 
Lymphadenectomy is not routinely performed, as the 
risk of lymph nodes metastasis is relatively low (6). 
Siu et al. reported a case of metastatic lymph nodes 
diagnosed by laparoscopic ultrasound and concluded 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Immunohistochemical studies for the vaginal 
tumour showed positive staining with a) S100, b) HMB45, c) 
Melan-A but d) negative for CK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: T2 weighted MR image in axial (a) and sagittal (b) views showing a well-circumscribed vaginal wall mass 
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that it is essential to exclude lymphatic metastasis 
before radical surgery (10). However, Gungor et al. 
was not able to demonstrate any lymph node 
metastasis in all four patients with vaginal melanoma 
following lymph node resection (8). In view of higher 
morbidity and mortality of lymph node resection, 
sentinel node biopsy is gaining popularity. 
Preoperative lymphoscintigraphy, with its high 
sensitivity up to 99%, aids in the identification of 
sentinel lymph node (11). The incidence of nodal 
recurrence following a false-negative lymphatic 
mapping and sentinel node biopsy in patients with 
tumor-negative sentinel nodes is low at 1.3% (11). 
Phan et al. suggested that sentinel lymph node biopsy 
should be considered in melanoma with Breslow depth 
of ≥ 0.76mm (12). 
 
Radiotherapy appeared to be as effective as surgery 
(2). It may be used as primary therapy when the 
tumour is surgically non-resectable or medically unfit.  
Radiotherapy after WLE is associated with lower local 
recurrence rate and increased survival (3,4). 
 
The role of chemotherapy and immunotherapy in the 
management of vaginal melanoma has not been fully 
established although some reports showed promising 
result (13). Combination chemotherapy such as 
Dartmouth regime (Dacarbazine, Carmustine, 
Cisplatin and Tamoxifen), BOLD (Bleomycin, 
Vincristine, Lomustine and Dacarbazine) and CVD 
regime (Cisplatin, Vinblastine and Dacarbazine) are 
frequently used. Lens and Eisen failed to demonstrate 
any significant benefit in survival between 
combination therapy and Dacarbazine alone (14). 
However, the use of combination chemotherapy may 
still be justified especially in the context of metastatic 
melanoma.  
 
Buchanan et al. in his review of 67 patients with 
primary vaginal melanoma, concluded that no 
significant difference in the outcome between various 
treatment approaches, namely WLE, radical surgery, 
radiation therapy or combination therapy (2). In 
contrast, Frumovitz et al. in his review of 37 women, 
concluded that survival was significantly longer in 
those treated surgically than those treated non-
surgically (3). Similar finding was reported by Miner 
et al. (6) On the other hand, combination of 
conservative surgery with radiotherapy has been 
suggested to prolong metastasis-free period and the 
overall survival rate (4). Thus, conservative resection 
of the gross disease would probably be the mainstay of 
treatment options for a better clinical outcome (6). 
Nevertheless, pelvic exenteration shall be reserved for 
cases of large tumour bulk whereby WLE is not 
feasible.  
One of the factors that influence the survival rate is the 
size of tumour. It was noted that tumour size less than 
3cm has a better mean survival compared to those 3cm 
and beyond (41 vs 12 months, p<0.0024) (2). Another 
review by Li et al. revealed that tumour size less than 
2cm was associated with longer survival rate (27.7 vs 
9.7 months) (15). They concluded that surgery was 
related to an overall improved survival. The general 
outcome of the disease would be more favorable if the 
diagnosis was made earlier and managed with 
combined modality treatment. 
 
Our patient underwent wide local resection. As the 
tumour size was 3 cm and beyond and the surgical 
margin was not clear, she was subjected for adjuvant 
radiotherapy and combination chemotherapy. 
Unfortunately, despite combined therapy, her disease 
progressed. As conclusion, though primary malignant 
vaginal melanoma is rare, its prognosis remains very 
poor despite multiple treatment modalities. 
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